ciglitazone
Sign in to saveAlso known as (+-)-5-{p-[(1-Methylcyclohexyl)methoxy]benzyl}-2,4-thiazolidinedione
Ciglitazone (INN) is a thiazolidinedione. Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
Research
627 papers- Anti-fibrotic effect of ciglitazone in HRV-induced airway remodelling cell model.Journal of cellular and molecular medicine · 2023
- Ciglitazone-a human PPARγ agonist-disrupts dorsoventral patterning in zebrafish.PeerJ · 2019
- Effect of ciglitazone on adipogenic transdifferentiation of bovine skeletal muscle satellite cells.Journal of animal science and technology · 2021
- Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.Cell death and differentiation · 2011
- Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1.European journal of pharmacology · 2014
via PubMed
~2 min read
Encyclopedic overview
1 sectionsContents
- References
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 404168235 | IUPAC_name = 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione | image = Ciglitazone.svg | image_class = skin-invert-image | width = 222
| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
Excerpted from Wikipedia’s “ciglitazone” article, available under the CC BY-SA 4.0 licence.